Dual modulation of bone formation and resorption with zoledronic acid-loaded biodegradable magnesium alloy implants improves osteoporotic fracture healing: An in vitro and in vivo study

2018 ◽  
Vol 65 ◽  
pp. 486-500 ◽  
Author(s):  
Guoyuan Li ◽  
Lei Zhang ◽  
Lei Wang ◽  
Guangyin Yuan ◽  
Kerong Dai ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Magnesium Alloy ◽  
Bone Formation ◽  
Fracture Healing ◽  
Osteoporotic Fracture ◽  
In Vivo Study ◽  
Biodegradable Magnesium

scholarly journals Biodegradable magnesium alloy with eddy thermal effect for effective and accurate magnetic hyperthermia ablation of tumors

2020 ◽  
Author(s):  
Nailin Yang ◽  
Fei Gong ◽  
Liang Cheng ◽  
Huali Lei ◽  
Wei Li ◽  
...  
Keyword(s):  
Magnesium Alloy ◽  
Thermal Effect ◽  
Field Intensity ◽  
Magnetic Hyperthermia ◽  
Low Field ◽  
Hyperthermia Therapy ◽  
Biodegradable Magnesium ◽  
First Time

Abstract Magnetic hyperthermia therapy (MHT) is able to ablate tumors using an alternating magnetic field (AMF) to heat up magnetocaloric agents (e.g. magnetic nanoparticles) administered into the tumors. For clinical applications, there is still a demand to find new magnetocaloric agents with strong AMF-induced heating performance and excellent biocompatibility. As a kind of biocompatible and biodegradable material, magnesium (Mg) and its alloys have been extensively used in the clinic as an implant metal. Herein, we discovered that the eddy thermal effect of the magnesium alloy (MgA) could be employed for MHT to effectively ablate tumors. Under low-field-intensity AMFs, MgA rods could be rapidly heated, resulting in a temperature increase in nearby tissues. Such AMF-induced eddy thermal heating of MgA could not only be used to kill tumor cells in vitro, but also be employed for effective and accurate ablation of tumors in vivo. In addition to killing tumors in mice, we further demonstrated that VX2 tumors of much larger sizes growing in rabbits after implantation of MgA rods could also be eliminated after exposure to an AMF, illustrating the ability of MgA-based MHT to kill large-sized tumors. Moreover, the implanted MgA rods showed excellent biocompatibility and ∼20% of their mass was degraded within three months. Our work thus discovered for the first time that non-magnetic biodegradable MgA, an extensively used implant metal in clinic, could be used for effective magnetic thermal ablation of tumors under a low-field-intensity AMF. Such a strategy could be readily translated into clinical use.

In vivo study of nanostructured akermanite/ PEO coating on biodegradable magnesium alloy for biomedical applications

2014 ◽  
Vol 103 (5) ◽  
pp. 1798-1808 ◽  
Author(s):  
Mehdi Razavi ◽  
Mohammadhossein Fathi ◽  
Omid Savabi ◽  
Daryoosh Vashaee ◽  
Lobat Tayebi
Keyword(s):  
Magnesium Alloy ◽  
Biomedical Applications ◽  
In Vivo Study ◽  
Biodegradable Magnesium

In Vivo Effects of Zoledronic Acid on Bone Remodeling.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3520-3520
Author(s):  
Samantha Pozzi ◽  
Teru Hideshima ◽  
Sonia Vallet ◽  
Siddhartha Mukherjee ◽  
Shweta Chhetri ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Formation ◽  
Bone Remodeling ◽  
Bone Disease ◽  
Molecular Mechanisms ◽  
Bone Mineralization ◽  
Whole Body ◽  
Mineral Density

Abstract Zoledronic acid (ZA) is an amino-bisphosphonate with very potent antiresorptive activity widely used in the treatment of multiple myeloma (MM) bone disease. Recently, the increasing incidence of osteonecrosis of the jaw and its possible association with prolonged use of amino-bisphosphonates such as ZA has been reported. Therefore, we here studied the effects of ZA on bone remodeling in vitro and in vivo. Although ZA has been shown to inhibit osteoclastogenesis and increase bone mineralization, data on its effects on osteoblastic activity and on bone formation are conflicting. To study the effects of ZA on osteoblasts (OB), 5 week old C57BL/6 mice were treated with low and high doses of ZA intraperitoneally (IP) weekly. The dose ranged from 0.05-1mg/kg, with the highest dose recapitulating a lifetime dose of ZA over a 5 year period in an adult MM patient. Blood was collected at baseline and weekly thereafter. IP calcein injections were administered to study bone formation rates. Consistent with its known effects on bone mass and density, in vivo DXA scans in ZA-treated animals demonstrated an increase in whole body bone mineral density (BMD). ZA treatment was associated with a dose-related increase in trabecular bone at the distal femur, evaluated by microCT and confirmed by static histomorphometry. ELISA assays showed a decrease in TRACP5B (bone resorption), as expected due to the anti-osteoclastic activity of ZA. In addition to osteoclast (OC) inhibition, mice treated with ZA also showed alterations in OB activity. Specifically, serum osteocalcin (a marker for bone formation) levels were lower in ZA treated mice, and dynamic histomorphometry confirmed decreased bone formation rates. In order to study the mechanism of our in vivo observations, we tested the effects of ZA on OB, OC, and bone marrow stromal cells (BMSCs) treated in vitro with ZA (0.01μM to 100μM) for 7, 14, and 21 days. Decreased viability during differentiation of both OB and OC was observed, without any significant effects on BMSCs. This was associated with decreased alkaline phosphatase activity, suggesting functional impairment of OB activity. Our data therefore suggests that ZA impairs OB number and activity, in addition to effects on OC and may impair normal physiologic bone remodeling. Ongoing studies will determine the molecular mechanisms whereby ZA mediates these sequelae and inform future studies of ZA use in patients with MM bone disease.

scholarly journals In vitro and in vivo studies on biodegradable magnesium alloy

2014 ◽  
Vol 24 (5) ◽  
pp. 466-471 ◽  
Author(s):  
Lida Hou ◽  
Zhen Li ◽  
Yu Pan ◽  
Li Du ◽  
Xinlin Li ◽  
...  
Keyword(s):  
Magnesium Alloy ◽  
In Vivo Studies ◽  
Biodegradable Magnesium
Sign in / Sign up

Export Citation Format

Share Document